Several studies have shown that the activation of the mTOCR1 signaling pathway is involved in ESCC tumor growth,[26] autophagy,[27] and therapeutic efficacy.[28] These findings further corroborated the m5C‐mediated epigenetic regulatory mechanism by which the YBX1/m5C‐SMOX‐mTOCR1 axis is involved in the initiation and progression of ESCC. Here, YBX1 is linked to neoplasm.